Publication:
Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice

dc.contributor.authorMartínez Rodrigo, Abel
dc.contributor.authorS. Dias, Daniel
dc.contributor.authorRibeiro, Patrícia A. F.
dc.contributor.authorRoatt, Bruno M.
dc.contributor.authorMas Zubiri, Alicia
dc.contributor.authorCarrión Herrero, Francisco Javier
dc.contributor.authorCoelho, Eduardo A. F.
dc.contributor.authorDomínguez Bernal, Gustavo Ramón
dc.date.accessioned2023-06-17T09:03:32Z
dc.date.available2023-06-17T09:03:32Z
dc.date.issued2019-11-14
dc.description.abstractLeishmania amazonensis is the aetiological agent of a broad spectrum of leishmaniosis in South America. It can cause not only numerous cases of cutaneous leishmaniosis but also diffuse cutaneous leishmaniosis. Considering the diversity of parasite species causing different forms of the disease that coexist in the same region, it is desirable to develop a vaccine capable of eliciting cross-protection. We have previously described the use of HisAK70 DNA vaccine for immunization of mice to assess the induction of a resistant phenotype against Leishmania major and infantum infections. In this study, we extended its application in the murine model of infection by using L. amazonensis promastigotes. Our data revealed that 14 weeks post-infection, HisAK70-vaccinated mice showed key biomarkers of protection, such as higher iNOS/arginase activity, IFN-γ/IL-10, IFN-γ/IL-4, and GM-CSF/IL-10 ratios, in addition to an IgG2a-type response when compared to the control group. These findings correlated with the presentation of lower footpad swelling and parasite burdens in the immunized compared to the control mice. Overall, this study suggests that immunization with HisAK70 may be considered a suitable tool to combat leishmaniosis as it is able to induce a potent cellular immune response, which allows to control the infection caused by L. amazonensis.
dc.description.departmentDepto. de Sanidad Animal
dc.description.facultyFac. de Veterinaria
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Economía y Competitividad (MINECO)
dc.description.sponsorshipComunidad de Madrid
dc.description.sponsorshipUniversidad Complutense de Madrid/Banco Santander
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/65123
dc.identifier.doi10.3390/vaccines7040183
dc.identifier.issn2076-393X
dc.identifier.officialurlhttps://doi.org/10.3390/vaccines7040183
dc.identifier.relatedurlhttps://www.mdpi.com/2076-393X/7/4/183
dc.identifier.urihttps://hdl.handle.net/20.500.14352/8061
dc.issue.number4
dc.journal.titleVaccines
dc.language.isoeng
dc.page.initial183
dc.publisherMDPI
dc.relation.projectIDAGL2013-44100R
dc.relation.projectIDPLATESA2-CM (S2018/BAA-4370
dc.relation.projectIDPR75/18-21558
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.keywordLeishmania amazonensis
dc.subject.keywordcross-protection
dc.subject.keywordleishmaniosis
dc.subject.keywordvaccine
dc.subject.keywordDNA
dc.subject.keywordHisAK70
dc.subject.ucmAnimales de laboratorio
dc.subject.ucmInmunología veterinaria
dc.subject.unesco3109.03 Inmunología
dc.titleImmunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice
dc.typejournal article
dc.volume.number7
dspace.entity.typePublication
relation.isAuthorOfPublication032c721f-5804-4b94-b573-701af816cfe2
relation.isAuthorOfPublicationc870c8b8-1a25-476d-8e05-2ac13abf6aef
relation.isAuthorOfPublication8207c445-ff65-45fc-9070-60fe6e14b5e2
relation.isAuthorOfPublicationabaef580-f831-4742-bfe3-1e02ba3a6594
relation.isAuthorOfPublication.latestForDiscovery032c721f-5804-4b94-b573-701af816cfe2
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
vaccines-07-00183.pdf
Size:
1.24 MB
Format:
Adobe Portable Document Format
Collections